Corcept CEO trust sells 12,837 CORT shares

Corcept Therapeutics’ Chief Executive Officer, Joseph K. Belanoff, reported a mix of open-market sales and estate-planning transfers involving the company’s common stock.

Rhea-AI Filing Summary

Corcept Therapeutics’ Chief Executive Officer, Joseph K. Belanoff, reported a mix of open-market sales and estate-planning transfers involving the company’s common stock. An entity associated with him, the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust, sold 12,837 shares at $69.74 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan, leaving 2,565,489 shares held by that trust.

Separately, there were gift transfers totaling 600,000 shares with no consideration. These included 300,000 shares transferred out of the revocable living trust, and 150,000 shares to each of two 2026 Grantor Retained Annuity Trusts for Joseph K. Belanoff and for his spouse, respectively. The filing notes that the CEO disclaims beneficial ownership of certain trust-held shares except to the extent of his pecuniary interest.

Insights

Equity analyst

Filing shows a small pre-planned sale plus large estate-planning gifts.

CEO-associated trusts reported selling 12,837 Corcept shares at $69.74 each and completing several bona fide gifts totaling 600,000 shares. The sale occurred from a revocable living trust, which still holds 2,565,489 shares afterward, indicating a substantial remaining position.

The open-market sale was executed pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024, suggesting the timing was pre-scheduled. The gifts to 2026 Grantor Retained Annuity Trusts look like estate- or tax-planning moves rather than market-driven decisions. Overall, the transactions appear routine and administrative rather than thesis-changing.

Insider Trade Summary 10b5-1

Net Seller: 12,837 shares

Net Sell 4 txns

Insider BELANOFF JOSEPH K

Role Chief Executive Officer

Sold 12,837 shs ($895K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,837	$69.74	$895K
Gift	Common Stock	300,000	$0.00	$0.00
Gift	Common Stock	150,000	$0.00	$0.00
Gift	Common Stock	150,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 150,000 shares (Indirect, Joseph K. Belanoff 2026 Grantor Retained Annuity Trust); Common Stock — 150,000 shares (Indirect, Katherine A. Blenko 2026 Grantor Retained Annuity Trust); Common Stock — 2,565,489 shares (Indirect, Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02)

Footnotes (6)

1. F1. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
2. F2. Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.
3. F3. Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.
4. F4. Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.
5. F5. Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.
6. F6. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

Key Figures

Open-market shares sold: 12,837 shares Sale price per share: $69.74 per share Shares held after sale: 2,565,489 shares +3 more

6 metrics

Open-market shares sold 12,837 shares Common Stock sale on 2026-06-01

Sale price per share $69.74 per share Open-market sale by revocable trust

Shares held after sale 2,565,489 shares Revocable living trust position post-transaction

Total gifted shares 600,000 shares Bona fide gifts on 2026-05-29

Gift to each 2026 GRAT 150,000 shares Transfers to Joseph and Katherine 2026 GRATs

Gift from revocable trust 300,000 shares Transfer from revocable living trust as gift

Key Terms

Rule 10b5-1 trading plan, Grantor Retained Annuity Trust, bona fide gift, pecuniary interest

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Grantor Retained Annuity Trust financial

"Joseph K. Belanoff 2026 Grantor Retained Annuity Trust"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

bona fide gift financial

"transaction_code_description": "Bona fide gift""

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

pecuniary interest financial

"disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Corcept Therapeutics (CORT) report in this Form 4?

The Form 4 reports an open-market sale of 12,837 Corcept shares at $69.74 per share by a revocable living trust plus 600,000 shares transferred as bona fide gifts to several 2026 Grantor Retained Annuity Trusts associated with CEO Joseph K. Belanoff.

Who conducted the Corcept (CORT) share sale and how many shares remain?

The sale was made by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust. It sold 12,837 shares and held 2,565,489 shares afterward. The filing states Dr. Belanoff has voting power but disclaims beneficial ownership except for his pecuniary interest.

Were the Corcept (CORT) insider share sales under a Rule 10b5-1 plan?

Yes. The filing states the 12,837-share open-market sale at $69.74 per share was executed under a Rule 10b5-1 trading plan adopted by Joseph K. Belanoff on November 26, 2024, indicating the transaction was pre-arranged.

What gifts of Corcept (CORT) stock were disclosed for CEO Joseph Belanoff?

The filing discloses 600,000 shares transferred as bona fide gifts with no consideration. These include 300,000 shares from the revocable living trust and 150,000 shares each to the Joseph K. Belanoff 2026 and Katherine A. Blenko 2026 Grantor Retained Annuity Trusts.

Does the Corcept (CORT) Form 4 show any remaining derivative positions for the CEO?

No derivative positions are listed in the derivative summary. The filing’s derivativeSummary section is empty, indicating no options, warrants, or other derivative securities are reported for Joseph K. Belanoff in this particular Form 4 snapshot.

How many Corcept (CORT) shares were involved in gifts versus sales in this filing?

The filing records an open-market sale of 12,837 shares and 600,000 shares disposed of as bona fide gifts. The transaction summary classifies one net sale transaction and three gift transfers, underscoring that most reported share movement reflects gifting rather than market selling.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BELANOFF JOSEPH K

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		G		300,000	D	$0.00	2,578,326	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(1)
Common Stock	05/29/2026		G(2)		150,000	A	$0.00	150,000	I	Joseph K. Belanoff 2026 Grantor Retained Annuity Trust(3)
Common Stock	05/29/2026		G(4)		150,000	A	$0.00	150,000	I	Katherine A. Blenko 2026 Grantor Retained Annuity Trust(5)
Common Stock	06/01/2026		S(6)		12,837	D	$69.74	2,565,489	I	Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

2. Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.

3. Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.

4. Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.

5. Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.

6. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)